% alzhub.org library filter
% Source: https://alzhub.org/research?author=Bittner+T&score_min=67
% 6 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{ostrowitzki2022-36121669,
  author  = {Ostrowitzki, S. and Bittner, T. and Sink, K. M. and Mackey, H. and Rabe, C. and Honig, L. S. and Cassetta, E. and Woodward, M. and others},
  title   = {{Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.2909},
  pmid    = {36121669},
  url     = {https://doi.org/10.1001/jamaneurol.2022.2909}
}

@article{neve2024-39177596,
  author  = {Neve, A. and Das, B. and Wojtowicz, J. and Huang, Z. and Bullain, S. and Watkin, M. and Lott, D. and Bittner, T. and others},
  title   = {{Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2024},
  doi     = {10.3233/jad-240221},
  pmid    = {39177596},
  url     = {https://doi.org/10.3233/jad-240221}
}

@article{wagemann2024-38683602,
  author  = {Wagemann, O. and Liu, H. and Wang, G. and Shi, X. and Bittner, T. and Scelsi, M. A. and Farlow, M. R. and Clifford, D. B. and others},
  title   = {{Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2024},
  doi     = {10.1001/jamaneurol.2024.0991},
  pmid    = {38683602},
  url     = {https://doi.org/10.1001/jamaneurol.2024.0991}
}

@article{janelidze2021-34542571,
  author  = {Janelidze, S. and Teunissen, C. E. and Zetterberg, H. and Allué, J. A. and Sarasa, L. and Eichenlaub, U. and Bittner, T. and Ovod, V. and others},
  title   = {{Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease}},
  journal = {JAMA neurology},
  year    = {2021},
  doi     = {10.1001/jamaneurol.2021.3180},
  pmid    = {34542571},
  url     = {https://doi.org/10.1001/jamaneurol.2021.3180}
}

@article{palmqvist2019-31233127,
  author  = {Palmqvist, S. and Janelidze, S. and Stomrud, E. and Zetterberg, H. and Karl, J. and Zink, K. and Bittner, T. and Mattsson, N. and others},
  title   = {{Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status}},
  journal = {JAMA neurology},
  year    = {2019},
  doi     = {10.1001/jamaneurol.2019.1632},
  pmid    = {31233127},
  url     = {https://doi.org/10.1001/jamaneurol.2019.1632}
}

@article{hansson2018-29499171,
  author  = {Hansson, O. and Seibyl, J. and Stomrud, E. and Zetterberg, H. and Trojanowski, J. Q. and Bittner, T. and Lifke, V. and Corradini, V. and others},
  title   = {{CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2018},
  doi     = {10.1016/j.jalz.2018.01.010},
  pmid    = {29499171},
  url     = {https://doi.org/10.1016/j.jalz.2018.01.010}
}